ES2032896T3 - Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina. - Google Patents

Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina.

Info

Publication number
ES2032896T3
ES2032896T3 ES198888107667T ES88107667T ES2032896T3 ES 2032896 T3 ES2032896 T3 ES 2032896T3 ES 198888107667 T ES198888107667 T ES 198888107667T ES 88107667 T ES88107667 T ES 88107667T ES 2032896 T3 ES2032896 T3 ES 2032896T3
Authority
ES
Spain
Prior art keywords
insulin
mixed crystals
des
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888107667T
Other languages
English (en)
Inventor
Michael Dr. Dorschug
Rainer Dr. Obermeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2032896T3 publication Critical patent/ES2032896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

POR CRISTALIZACION EN SOLUCION ACUOSA DENTRO DE UN INTERVALO ESTRECHO DE PH (ENTRE 5,5 Y 6,9) SE OBTIENEN CRISTALES MIXTOS DE: A) INSULINA NATIVA, DES-PHE-B1-INSULINA, DES-THR-B30-INSULINA (HUMANA) O DES-ALA-B30-INSULINA (PORCINA, VACUNA) Y B) AL MENOS UNA INSULINA MODIFICADA BASICAMENTE EN EL C-TERMINAL DE LA CADENA B, PREFERENTEMENTE INSULINA HUMANA (A) E INSULINA HUMANA ARG-B31 Y/O INSULINA HUMANA ARG2 (B31-32) (B). LOS CRISTALES MIXTOS PRESENTAN UN PERFIL DE RETARDO MEDIO ESPECIAL Y RESULTAN ADECUADOS PARA EL TRATAMIENTO DE LA DIABETES MELLITUS.
ES198888107667T 1987-05-22 1988-05-13 Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina. Expired - Lifetime ES2032896T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873717370 DE3717370A1 (de) 1987-05-22 1987-05-22 Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2032896T3 true ES2032896T3 (es) 1993-03-01

Family

ID=6328227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888107667T Expired - Lifetime ES2032896T3 (es) 1987-05-22 1988-05-13 Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina.

Country Status (20)

Country Link
US (1) US5028587A (es)
EP (1) EP0291863B1 (es)
JP (1) JPS63303930A (es)
KR (1) KR880013572A (es)
AT (1) ATE71842T1 (es)
AU (1) AU601280B2 (es)
CA (1) CA1335924C (es)
DE (2) DE3717370A1 (es)
DK (1) DK278088A (es)
ES (1) ES2032896T3 (es)
FI (1) FI93797C (es)
GR (1) GR3004344T3 (es)
HU (1) HU203840B (es)
IE (1) IE60649B1 (es)
IL (1) IL86452A (es)
NO (1) NO175641C (es)
NZ (1) NZ224715A (es)
PH (1) PH25587A (es)
PT (1) PT87523B (es)
ZA (1) ZA883599B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
DE69221725T2 (de) * 1991-05-24 1997-12-18 Amylin Pharmaceuticals, Inc., San Diego, Calif. Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
BR0207422A (pt) * 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
EG12098A (en) * 1974-04-13 1980-12-31 Hoechst Ag New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung

Also Published As

Publication number Publication date
DK278088D0 (da) 1988-05-20
AU1648788A (en) 1988-11-24
ZA883599B (en) 1989-01-25
DE3867903D1 (de) 1992-03-05
HU203840B (en) 1991-10-28
EP0291863B1 (de) 1992-01-22
IL86452A0 (en) 1988-11-15
HUT46546A (en) 1988-11-28
PH25587A (en) 1991-08-08
EP0291863A2 (de) 1988-11-23
FI93797B (fi) 1995-02-28
NO882207L (no) 1988-11-23
NZ224715A (en) 1990-04-26
CA1335924C (en) 1995-06-13
PT87523B (pt) 1992-09-30
PT87523A (pt) 1989-05-31
DE3717370A1 (de) 1988-12-01
NO882207D0 (no) 1988-05-20
FI882354A (fi) 1988-11-23
DK278088A (da) 1988-11-23
FI93797C (fi) 1995-06-12
NO175641C (no) 1994-11-09
EP0291863A3 (en) 1990-04-04
IL86452A (en) 1993-02-21
IE881522L (en) 1988-11-22
ATE71842T1 (de) 1992-02-15
JPS63303930A (ja) 1988-12-12
IE60649B1 (en) 1994-08-10
NO175641B (es) 1994-08-01
GR3004344T3 (es) 1993-03-31
AU601280B2 (en) 1990-09-06
KR880013572A (ko) 1988-12-21
FI882354A0 (fi) 1988-05-19
US5028587A (en) 1991-07-02

Similar Documents

Publication Publication Date Title
ES2032896T3 (es) Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina.
NO875299L (no) Insulinpreparat for ikke-paranteral administrasjon.
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
ZA845620B (en) Novel insulin derivatives,processes for their preparation and their use,and pharmaceutical agents for the treatment of diabetes mellitus
NO895188D0 (no) Polyamid/gummiblanding og fremgangsmaate for dens fremstilling.
DK275585A (da) Hidtil ukendte calciumsalte
ES2022704B3 (es) Procedimiento para la obtencion de preparaciones colorantes acuosas concentradas de colorantes organicos.
ATE84716T1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelialgewebekrankheiten.
FI885488A0 (fi) 2,2-difluorisyklopropyylietaanijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö tuholaisten torjunta-aineina
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
KR900012933A (ko) 당뇨병 및 과혈당증 치료제로 유용한 화합물 및 이의 제조방법
DE58903876D1 (de) Riboflavin-4'5'-cyclo-phosphorsaeureesterchlorid, dessen herstellung und verwendung zur herstellung von riboflavin-5'-phosphat (5'-fmn) bzw. dessen natriumsalz.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
AU5581186A (en) Protein absorption enhancing agent
ES2011472B3 (es) Procedimiento para el tratamiento de soluciones acuosas producidas en la carboxilacion de compuestos olefinicos no saturados.
UA8036A1 (uk) Спосіб одержання похідних тіазолу або їх кислотно-аддітивних солей
IT8322478A0 (it) Procedimento per la produzione di sostanze proteiche esenti da composti porfirinici da sangue di macellazione.
NO891156L (no) Superaktive humane insulinanaloger.
IT1243577B (it) Uso disseccante fogliare per la patata a base di dnoc (dinitro orto cresolo) e suoi derivati.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 291863

Country of ref document: ES